Segment disclosures

Company overview

Amneal Pharmaceuticals, Inc.

Each reported dimension combination stays separate. Revenue and operating income are shown as reported, with their dates and sources.

Revenue · Reported segment facts

140 dimension combinations 780 retained observations 13 reported periods Partial retained history

Counts describe retained dimensioned rows only. Periods and members can change across reports, and this view does not infer missing values or expected segment totals.

Operating Segments · Affordable Medicines Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30489913000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30913150000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31423237000 USD20260507Open filing evidence
2025-01-01 – 2025-12-311745524000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30460741000 USD20251106Open filing evidence
2025-01-01 – 2025-09-301308874000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30433425000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30848133000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31414708000 USD20260507Open filing evidence
2024-01-01 – 2024-12-311685263000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30427345000 USD20251106Open filing evidence
2024-01-01 – 2024-09-301245967000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30427328000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30818622000 USD20250807Open filing evidence
2024-01-01 – 2024-03-31391294000 USD20250507Open filing evidence
2023-01-01 – 2023-12-311471401000 USD20260227Open filing evidence

Operating Segments · Amneal Specialty Pharma Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AmnealSpecialtyPharmaSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30149295000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30282560000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31133265000 USD20260507Open filing evidence
2025-07-01 – 2025-09-30125240000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30361580000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30128043000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30236340000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31108297000 USD20260507Open filing evidence
2024-07-01 – 2024-09-30115638000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30324913000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30104041000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30209275000 USD20250807Open filing evidence
2024-01-01 – 2024-03-31105234000 USD20250507Open filing evidence
2023-07-01 – 2023-09-3097304000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30285976000 USD20241112Open filing evidence

Operating Segments · Av KARE Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30156989000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30323006000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31166017000 USD20260507Open filing evidence
2025-01-01 – 2025-12-31744728000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30198532000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30533987000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30163040000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30335455000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31172415000 USD20260507Open filing evidence
2024-01-01 – 2024-12-31662945000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30159485000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30492559000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30170411000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30333074000 USD20250807Open filing evidence
2024-01-01 – 2024-03-31162663000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31531749000 USD20260227Open filing evidence
2023-07-01 – 2023-09-30131879000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30382286000 USD20241112Open filing evidence

Operating Segments · Generics Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-30427345000 USD20241112Open filing evidence
2024-01-01 – 2024-09-301245967000 USD20241112Open filing evidence
2024-04-01 – 2024-06-30427328000 USD20240809Open filing evidence
2024-01-01 – 2024-06-30818622000 USD20240809Open filing evidence
2024-01-01 – 2024-03-31391294000 USD20240508Open filing evidence
2023-07-01 – 2023-09-30390857000 USD20241112Open filing evidence
2023-01-01 – 2023-09-301108364000 USD20241112Open filing evidence

Operating Segments · Specialty Segment

Consolidation Items · Statement Business Segments

Source dimensions srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31528508000 USD20260227Open filing evidence
2024-01-01 – 2024-12-31445749000 USD20260227Open filing evidence
2023-01-01 – 2023-12-31390457000 USD20260227Open filing evidence

Antiviral · Generics Segment · US

Product Or Service · Statement Business Segments · Statement Geographical

Source dimensions srt:ProductOrServiceAxis=amrx:AntiviralMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-307150000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3036221000 USD20231109Open filing evidence

Biosimilar · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:BiosimilarMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31100228000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3017009000 USD20251106Open filing evidence
2025-01-01 – 2025-09-3070797000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3025248000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3053788000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31125422000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3030678000 USD20251106Open filing evidence
2024-01-01 – 2024-09-3086870000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3029500000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3056192000 USD20250807Open filing evidence
2023-01-01 – 2023-12-3165923000 USD20260227Open filing evidence

Biosimilar · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:BiosimilarMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3029128000 USD20260806Open filing evidence
2026-01-01 – 2026-06-3051429000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3122301000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3025248000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3053788000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3128540000 USD20260507Open filing evidence

Cardiovascular System · Generics Segment · US

Product Or Service · Statement Business Segments · Statement Geographical

Source dimensions srt:ProductOrServiceAxis=amrx:CardiovascularSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3032459000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3098108000 USD20231109Open filing evidence

Central Nervous System · US · Specialty Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31333417000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3077631000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30228666000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3083425000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30151035000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31280174000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3073401000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30203583000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3063906000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30130182000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31249981000 USD20260227Open filing evidence

Central Nervous System · Specialty Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3095344000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30178727000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3183383000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3083425000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30151035000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3167610000 USD20260507Open filing evidence

Ephinephrine Auto Injector · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31232796000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3078940000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30193694000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3066594000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30114754000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31209497000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3070690000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30171589000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3058281000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30100899000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31160853000 USD20260227Open filing evidence

Ephinephrine Auto Injector · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3062214000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30104126000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3141912000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3066594000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30114754000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3148160000 USD20260507Open filing evidence

Gastroenterology · US · Generics Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:GastroenterologyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-3118197000 USD20240508Open filing evidence

Government Label · US · Av KARE Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31270105000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3087755000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30183313000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3045418000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3095558000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31159957000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3041936000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30113098000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3036210000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3071162000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31121829000 USD20260227Open filing evidence

Government Label · Av KARE Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3050207000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30110156000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3159949000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3045418000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3095558000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3150140000 USD20260507Open filing evidence

Government Label · Av KARE Segment · US

Product Or Service · Statement Business Segments · Statement Geographical

Source dimensions srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3032764000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3087150000 USD20231109Open filing evidence

Hormonal Allergy · US · Generics Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-31107714000 USD20240508Open filing evidence

Hormonal Allergy · US · Specialty Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31154927000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3037685000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30107302000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3035418000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3069617000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31130426000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3032283000 USD20251106Open filing evidence
2024-01-01 – 2024-09-3093433000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3031775000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3061150000 USD20250807Open filing evidence
2024-01-01 – 2024-03-3129375000 USD20240508Open filing evidence
2023-01-01 – 2023-12-31110486000 USD20260227Open filing evidence

Hormonal Allergy · Specialty Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3042099000 USD20260806Open filing evidence
2026-01-01 – 2026-06-3078031000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3135932000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3035418000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3069617000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3134199000 USD20260507Open filing evidence

Injectable · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:InjectableMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31161239000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3054368000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30123802000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3034646000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3069434000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31165430000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3043169000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30117472000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3039081000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3074303000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31141854000 USD20260227Open filing evidence

Injectable · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:InjectableMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3056783000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30106721000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3149938000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3034646000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3069434000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3134788000 USD20260507Open filing evidence

Institutional · US · Av KARE Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:InstitutionalMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3135376000 USD20260227Open filing evidence
2025-07-01 – 2025-09-305853000 USD20251106Open filing evidence
2025-01-01 – 2025-09-3026994000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3010132000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3021141000 USD20250807Open filing evidence
2024-01-01 – 2024-12-3142750000 USD20260227Open filing evidence
2024-07-01 – 2024-09-309394000 USD20251106Open filing evidence
2024-01-01 – 2024-09-3032020000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3011768000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3022626000 USD20250807Open filing evidence
2023-01-01 – 2023-12-3138016000 USD20260227Open filing evidence

Institutional · Av KARE Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:InstitutionalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3012112000 USD20260806Open filing evidence
2026-01-01 – 2026-06-3021931000 USD20260806Open filing evidence
2026-01-01 – 2026-03-319819000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3010132000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3021141000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3111009000 USD20260507Open filing evidence

Institutional · Av KARE Segment · US

Product Or Service · Statement Business Segments · Statement Geographical

Source dimensions srt:ProductOrServiceAxis=amrx:InstitutionalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3010551000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3028395000 USD20231109Open filing evidence

International · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:InternationalMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3112125000 USD20260227Open filing evidence
2025-07-01 – 2025-09-306288000 USD20251106Open filing evidence
2025-01-01 – 2025-09-309423000 USD20251106Open filing evidence
2025-04-01 – 2025-06-301901000 USD20250807Open filing evidence
2025-01-01 – 2025-06-303135000 USD20250807Open filing evidence
2024-01-01 – 2024-12-318952000 USD20260227Open filing evidence
2024-07-01 – 2024-09-304507000 USD20251106Open filing evidence
2024-01-01 – 2024-09-307658000 USD20251106Open filing evidence
2024-04-01 – 2024-06-301430000 USD20250807Open filing evidence
2024-01-01 – 2024-06-303151000 USD20250807Open filing evidence
2023-01-01 – 2023-12-312165000 USD20260227Open filing evidence

International · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:InternationalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-307613000 USD20260806Open filing evidence
2026-01-01 – 2026-06-3012932000 USD20260806Open filing evidence
2026-01-01 – 2026-03-315319000 USD20260507Open filing evidence
2025-04-01 – 2025-06-301901000 USD20260806Open filing evidence
2025-01-01 – 2025-06-303135000 USD20260806Open filing evidence
2025-01-01 – 2025-03-311234000 USD20260507Open filing evidence

License Agreement · US · Specialty Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31500000 USD20260227Open filing evidence
2025-07-01 – 2025-09-300 USD20251106Open filing evidence
2025-01-01 – 2025-09-30500000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30500000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30500000 USD20250807Open filing evidence
2024-01-01 – 2024-12-316527000 USD20260227Open filing evidence
2024-07-01 – 2024-09-302048000 USD20251106Open filing evidence
2024-01-01 – 2024-09-306527000 USD20251106Open filing evidence
2024-04-01 – 2024-06-300 USD20250807Open filing evidence
2024-01-01 – 2024-06-304479000 USD20250807Open filing evidence
2023-01-01 – 2023-12-310 USD20260227Open filing evidence

License Agreement · Specialty Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-300 USD20260806Open filing evidence
2026-01-01 – 2026-06-300 USD20260806Open filing evidence
2025-04-01 – 2025-06-30500000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30500000 USD20260806Open filing evidence

Metabolic Disease Endocrine · US · Generics Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-3111185000 USD20240508Open filing evidence

Oncology · US · Generics Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OncologyMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-3138533000 USD20240508Open filing evidence

Oncology · Generics Segment · US

Product Or Service · Statement Business Segments · Statement Geographical

Source dimensions srt:ProductOrServiceAxis=amrx:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3037722000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3076846000 USD20231109Open filing evidence

Oral Liquid · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OralLiquidMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3172821000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3016415000 USD20251106Open filing evidence
2025-01-01 – 2025-09-3057842000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3017879000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3041427000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31103421000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3022543000 USD20251106Open filing evidence
2024-01-01 – 2024-09-3078568000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3024096000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3056025000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31111045000 USD20260227Open filing evidence

Oral Liquid · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OralLiquidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3010371000 USD20260806Open filing evidence
2026-01-01 – 2026-06-3022463000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3112092000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3017879000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3041427000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3123548000 USD20260507Open filing evidence

Oral Solid · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OralSolidMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31726383000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30180460000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30537675000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30178262000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30357215000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31689436000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30161215000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30506484000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30175956000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30345269000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31649998000 USD20260227Open filing evidence

Oral Solid · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OralSolidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30175172000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30346272000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31171100000 USD20260507Open filing evidence
2025-04-01 – 2025-06-30178262000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30357215000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31178953000 USD20260507Open filing evidence

Other Dosage Forms · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31252421000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3059662000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30184269000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3068185000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30124607000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31202188000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3050652000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30143213000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3049287000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3092561000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31180479000 USD20260227Open filing evidence

Other Dosage Forms · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3081594000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30128206000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3146612000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3068185000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30124607000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3156422000 USD20260507Open filing evidence

Other Therapeutic Classes · US · Specialty Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3139664000 USD20260227Open filing evidence
2025-07-01 – 2025-09-309924000 USD20251106Open filing evidence
2025-01-01 – 2025-09-3025112000 USD20251106Open filing evidence
2025-04-01 – 2025-06-308700000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3015188000 USD20250807Open filing evidence
2024-01-01 – 2024-12-3128622000 USD20260227Open filing evidence
2024-07-01 – 2024-09-307906000 USD20251106Open filing evidence
2024-01-01 – 2024-09-3021370000 USD20251106Open filing evidence
2024-04-01 – 2024-06-308360000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3013464000 USD20250807Open filing evidence
2023-01-01 – 2023-12-3129990000 USD20260227Open filing evidence

Other Therapeutic Classes · Generics Segment · US

Product Or Service · Statement Business Segments · Statement Geographical

Source dimensions srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3027270000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3080974000 USD20231109Open filing evidence

Other Therapeutic Classes · Specialty Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3011852000 USD20260806Open filing evidence
2026-01-01 – 2026-06-3025802000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3113950000 USD20260507Open filing evidence
2025-04-01 – 2025-06-308700000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3015188000 USD20260806Open filing evidence
2025-01-01 – 2025-03-316488000 USD20260507Open filing evidence

Other Therapeutic Classes · Specialty Segment · US

Product Or Service · Statement Business Segments · Statement Geographical

Source dimensions srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3129990000 USD20240314Open filing evidence
2023-07-01 – 2023-09-307668000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3022864000 USD20231109Open filing evidence

Subtotal Dosage Forms · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-311733399000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30454453000 USD20251106Open filing evidence
2025-01-01 – 2025-09-301299451000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30431524000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30844998000 USD20250807Open filing evidence
2024-01-01 – 2024-12-311676311000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30422838000 USD20251106Open filing evidence
2024-01-01 – 2024-09-301238309000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30425898000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30815471000 USD20250807Open filing evidence
2023-01-01 – 2023-12-311469236000 USD20260227Open filing evidence

Subtotal Dosage Forms · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30482300000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30900218000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31417918000 USD20260507Open filing evidence
2025-04-01 – 2025-06-30431524000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30844998000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31413474000 USD20260507Open filing evidence

Subtotal Therapeutic Classes · US · Specialty Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31528008000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30125240000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30361080000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30127543000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30235840000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31439222000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30113590000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30318386000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30104041000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30204796000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31390457000 USD20260227Open filing evidence

Subtotal Therapeutic Classes · Specialty Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-30149295000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30282560000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31133265000 USD20260507Open filing evidence
2025-04-01 – 2025-06-30127543000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30235840000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31108297000 USD20260507Open filing evidence

Transdermal · US · Affordable Medicines Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:TransdermalMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31187511000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3047599000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30131372000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3040710000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3083773000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31180917000 USD20260227Open filing evidence
2024-07-01 – 2024-09-3043891000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30134113000 USD20251106Open filing evidence
2024-04-01 – 2024-06-3049697000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3090222000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31159084000 USD20260227Open filing evidence

Transdermal · Affordable Medicines Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=amrx:TransdermalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3067038000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30141001000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3173963000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3040710000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3083773000 USD20260806Open filing evidence
2025-01-01 – 2025-03-3143063000 USD20260507Open filing evidence

Distribution Service · US · Av KARE Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-31408456000 USD20260227Open filing evidence
2025-07-01 – 2025-09-3096216000 USD20251106Open filing evidence
2025-01-01 – 2025-09-30300774000 USD20251106Open filing evidence
2025-04-01 – 2025-06-3099663000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30204558000 USD20250807Open filing evidence
2024-01-01 – 2024-12-31433981000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30101605000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30327453000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30116135000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30225848000 USD20250807Open filing evidence
2023-01-01 – 2023-12-31347406000 USD20260227Open filing evidence

Distribution Service · Av KARE Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-3086930000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30176079000 USD20260806Open filing evidence
2026-01-01 – 2026-03-3189149000 USD20260507Open filing evidence
2025-04-01 – 2025-06-3099663000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30204558000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31104895000 USD20260507Open filing evidence

Product And Service Other · US · Av KARE Segment

Product Or Service · Statement Geographical · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-3130791000 USD20260227Open filing evidence
2025-07-01 – 2025-09-308708000 USD20251106Open filing evidence
2025-01-01 – 2025-09-3022906000 USD20251106Open filing evidence
2025-04-01 – 2025-06-307827000 USD20250807Open filing evidence
2025-01-01 – 2025-06-3014198000 USD20250807Open filing evidence
2024-01-01 – 2024-12-3126257000 USD20260227Open filing evidence
2024-07-01 – 2024-09-306550000 USD20251106Open filing evidence
2024-01-01 – 2024-09-3019988000 USD20251106Open filing evidence
2024-04-01 – 2024-06-306298000 USD20250807Open filing evidence
2024-01-01 – 2024-06-3013438000 USD20250807Open filing evidence
2023-01-01 – 2023-12-3124498000 USD20260227Open filing evidence

Product And Service Other · Av KARE Segment

Product Or Service · Statement Business Segments

Source dimensions srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2026-04-01 – 2026-06-307740000 USD20260806Open filing evidence
2026-01-01 – 2026-06-3014840000 USD20260806Open filing evidence
2026-01-01 – 2026-03-317100000 USD20260507Open filing evidence
2025-04-01 – 2025-06-307827000 USD20260806Open filing evidence
2025-01-01 – 2025-06-3014198000 USD20260806Open filing evidence
2025-01-01 – 2025-03-316371000 USD20260507Open filing evidence

US · Anti Infective · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-305454000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3017966000 USD20241112Open filing evidence
2024-04-01 – 2024-06-306402000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3012512000 USD20240809Open filing evidence
2023-07-01 – 2023-09-307382000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3018648000 USD20241112Open filing evidence

US · Antiviral · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:AntiviralMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-304371000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3012544000 USD20241112Open filing evidence
2024-04-01 – 2024-06-304307000 USD20240809Open filing evidence
2024-01-01 – 2024-06-308173000 USD20240809Open filing evidence
2023-07-01 – 2023-09-307150000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3036221000 USD20241112Open filing evidence

US · Biosimilar · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:BiosimilarMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3128540000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31125422000 USD20250228Open filing evidence
2024-01-01 – 2024-03-3126692000 USD20250507Open filing evidence
2023-01-01 – 2023-12-3165923000 USD20250228Open filing evidence

US · Cardiovascular System · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CardiovascularSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-3036420000 USD20241112Open filing evidence
2024-01-01 – 2024-09-30123629000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3041331000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3087209000 USD20240809Open filing evidence
2024-01-01 – 2024-03-3145878000 USD20240508Open filing evidence
2023-07-01 – 2023-09-3032459000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3098108000 USD20241112Open filing evidence

US · Central Nervous System · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-30108962000 USD20241112Open filing evidence
2024-01-01 – 2024-09-30340186000 USD20241112Open filing evidence
2024-04-01 – 2024-06-30121768000 USD20240809Open filing evidence
2024-01-01 – 2024-06-30231224000 USD20240809Open filing evidence
2023-07-01 – 2023-09-3096587000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30264773000 USD20241112Open filing evidence

US · Central Nervous System · Specialty Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3167610000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31280174000 USD20250228Open filing evidence
2024-07-01 – 2024-09-3073401000 USD20241112Open filing evidence
2024-01-01 – 2024-09-30203583000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3063906000 USD20240809Open filing evidence
2024-01-01 – 2024-06-30130182000 USD20240809Open filing evidence
2024-01-01 – 2024-03-3166276000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31249981000 USD20250228Open filing evidence
2023-07-01 – 2023-09-3061142000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30180844000 USD20241112Open filing evidence

US · Dermatology · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:DermatologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-3019280000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3058829000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3020574000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3039549000 USD20240809Open filing evidence
2023-07-01 – 2023-09-3017279000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3053232000 USD20241112Open filing evidence

US · Ephinephrine Auto Injector · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3148160000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31209497000 USD20250228Open filing evidence
2024-01-01 – 2024-03-3142618000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31160853000 USD20250228Open filing evidence

US · Gastroenterology · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:GastroenterologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-3014467000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3045391000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3012727000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3030924000 USD20240809Open filing evidence
2023-07-01 – 2023-09-3018858000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3053127000 USD20241112Open filing evidence

US · Government Label · Av KARE Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:GovernmentLabelMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3150140000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31159957000 USD20250228Open filing evidence
2024-07-01 – 2024-09-3041936000 USD20241112Open filing evidence
2024-01-01 – 2024-09-30113098000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3036210000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3071162000 USD20240809Open filing evidence
2024-01-01 – 2024-03-3134952000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31121829000 USD20250228Open filing evidence
2023-07-01 – 2023-09-3032764000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3087150000 USD20241112Open filing evidence

US · Hormonal Allergy · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-30132643000 USD20241112Open filing evidence
2024-01-01 – 2024-09-30363930000 USD20241112Open filing evidence
2024-04-01 – 2024-06-30123573000 USD20240809Open filing evidence
2024-01-01 – 2024-06-30231287000 USD20240809Open filing evidence
2023-07-01 – 2023-09-30126425000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30357711000 USD20241112Open filing evidence

US · Hormonal Allergy · Specialty Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3134199000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31130426000 USD20250228Open filing evidence
2024-07-01 – 2024-09-3032283000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3093433000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3031775000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3061150000 USD20240809Open filing evidence
2024-01-01 – 2024-03-3129375000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31110486000 USD20250228Open filing evidence
2023-07-01 – 2023-09-3028494000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3082268000 USD20241112Open filing evidence

US · Injectable · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:InjectableMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3134788000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31165430000 USD20250228Open filing evidence
2024-01-01 – 2024-03-3135222000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31141854000 USD20250228Open filing evidence

US · Institutional · Av KARE Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:InstitutionalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3111009000 USD20250507Open filing evidence
2024-01-01 – 2024-12-3142750000 USD20250228Open filing evidence
2024-07-01 – 2024-09-309394000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3032020000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3011768000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3022626000 USD20240809Open filing evidence
2024-01-01 – 2024-03-3110858000 USD20250507Open filing evidence
2023-01-01 – 2023-12-3138016000 USD20250228Open filing evidence
2023-07-01 – 2023-09-3010551000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3028395000 USD20241112Open filing evidence

US · International · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:InternationalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-311234000 USD20250507Open filing evidence
2024-01-01 – 2024-12-318952000 USD20250228Open filing evidence
2024-01-01 – 2024-03-311721000 USD20250507Open filing evidence
2023-01-01 – 2023-12-312165000 USD20250228Open filing evidence

US · License Agreement · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-12-310 USD20250228Open filing evidence
2023-01-01 – 2023-12-310 USD20250228Open filing evidence

US · License Agreement · Specialty Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-310 USD20250507Open filing evidence
2024-01-01 – 2024-12-316527000 USD20250228Open filing evidence
2024-07-01 – 2024-09-302048000 USD20241112Open filing evidence
2024-01-01 – 2024-09-306527000 USD20241112Open filing evidence
2024-04-01 – 2024-06-300 USD20240809Open filing evidence
2024-01-01 – 2024-06-304479000 USD20240809Open filing evidence
2024-01-01 – 2024-03-314479000 USD20250507Open filing evidence
2023-01-01 – 2023-12-310 USD20250228Open filing evidence
2023-07-01 – 2023-09-300 USD20241112Open filing evidence
2023-01-01 – 2023-09-300 USD20241112Open filing evidence

US · Metabolic Disease Endocrine · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-308640000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3029298000 USD20241112Open filing evidence
2024-04-01 – 2024-06-309473000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3020658000 USD20240809Open filing evidence
2023-07-01 – 2023-09-3011026000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3035227000 USD20241112Open filing evidence

US · Oncology · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OncologyMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-3044471000 USD20241112Open filing evidence
2024-01-01 – 2024-09-30131270000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3048266000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3086799000 USD20240809Open filing evidence
2023-07-01 – 2023-09-3037722000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3076846000 USD20241112Open filing evidence

US · Oral Liquid · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OralLiquidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3123548000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31103421000 USD20250228Open filing evidence
2024-01-01 – 2024-03-3131929000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31111045000 USD20250228Open filing evidence

US · Oral Solid · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OralSolidMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-31178953000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31689436000 USD20250228Open filing evidence
2024-01-01 – 2024-03-31169313000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31649998000 USD20250228Open filing evidence

US · Other Dosage Forms · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3156422000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31202188000 USD20250228Open filing evidence
2024-01-01 – 2024-03-3143274000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31180479000 USD20250228Open filing evidence

US · Other Therapeutic Classes · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-3038670000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3081263000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3024070000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3042593000 USD20240809Open filing evidence
2023-07-01 – 2023-09-3027270000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3080974000 USD20241112Open filing evidence

US · Other Therapeutic Classes · Specialty Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-316488000 USD20250507Open filing evidence
2024-01-01 – 2024-12-3128622000 USD20250228Open filing evidence
2024-07-01 – 2024-09-307906000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3021370000 USD20241112Open filing evidence
2024-04-01 – 2024-06-308360000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3013464000 USD20240809Open filing evidence
2024-01-01 – 2024-03-315104000 USD20250507Open filing evidence
2023-01-01 – 2023-12-3129990000 USD20250228Open filing evidence
2023-07-01 – 2023-09-307668000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3022864000 USD20241112Open filing evidence

US · Respiratory · Generics Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:RespiratoryMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-309459000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3034002000 USD20241112Open filing evidence
2024-04-01 – 2024-06-3013407000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3024543000 USD20240809Open filing evidence
2023-07-01 – 2023-09-307832000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3031783000 USD20241112Open filing evidence

US · Subtotal Dosage Forms · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-31413474000 USD20250507Open filing evidence
2024-01-01 – 2024-12-311676311000 USD20250228Open filing evidence
2024-01-01 – 2024-03-31389573000 USD20250507Open filing evidence
2023-01-01 – 2023-12-311469236000 USD20250228Open filing evidence

US · Subtotal Therapeutic Classes · Specialty Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember;us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-31108297000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31439222000 USD20250228Open filing evidence
2024-01-01 – 2024-03-31100755000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31390457000 USD20250228Open filing evidence

US · Transdermal · Affordable Medicines Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:TransdermalMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-3143063000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31180917000 USD20250228Open filing evidence
2024-01-01 – 2024-03-3140525000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31159084000 USD20250228Open filing evidence

US · Distribution Service · Av KARE Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-31104895000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31433981000 USD20250228Open filing evidence
2024-07-01 – 2024-09-30101605000 USD20241112Open filing evidence
2024-01-01 – 2024-09-30327453000 USD20241112Open filing evidence
2024-04-01 – 2024-06-30116135000 USD20240809Open filing evidence
2024-01-01 – 2024-06-30225848000 USD20240809Open filing evidence
2024-01-01 – 2024-03-31109713000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31347406000 USD20250228Open filing evidence
2023-07-01 – 2023-09-3081904000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30248929000 USD20241112Open filing evidence

US · Product And Service Other · Av KARE Segment

Statement Geographical · Product Or Service · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-03-316371000 USD20250507Open filing evidence
2024-01-01 – 2024-12-3126257000 USD20250228Open filing evidence
2024-07-01 – 2024-09-306550000 USD20241112Open filing evidence
2024-01-01 – 2024-09-3019988000 USD20241112Open filing evidence
2024-04-01 – 2024-06-306298000 USD20240809Open filing evidence
2024-01-01 – 2024-06-3013438000 USD20240809Open filing evidence
2024-01-01 – 2024-03-317140000 USD20250507Open filing evidence
2023-01-01 – 2023-12-3124498000 USD20250228Open filing evidence
2023-07-01 – 2023-09-306660000 USD20241112Open filing evidence
2023-01-01 – 2023-09-3017812000 USD20241112Open filing evidence

US · Affordable Medicines Segment

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2025-01-01 – 2025-12-311745524000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30460741000 USD20251106Open filing evidence
2025-01-01 – 2025-09-301308874000 USD20251106Open filing evidence
2025-04-01 – 2025-06-30433425000 USD20250807Open filing evidence
2025-01-01 – 2025-06-30848133000 USD20250807Open filing evidence
2025-01-01 – 2025-03-31414708000 USD20250507Open filing evidence
2024-01-01 – 2024-12-311685263000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30427345000 USD20251106Open filing evidence
2024-01-01 – 2024-09-301245967000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30427328000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30818622000 USD20250807Open filing evidence
2024-01-01 – 2024-03-31391294000 USD20250507Open filing evidence
2023-01-01 – 2023-12-311471401000 USD20260227Open filing evidence

US · Av KARE Segment · Government Label

Statement Geographical · Statement Business Segments · Product Or Service

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=amrx:GovernmentLabelMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31121829000 USD20240314Open filing evidence

US · Generics Segment · Anti Infective

Statement Geographical · Statement Business Segments · Product Or Service

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-316110000 USD20240508Open filing evidence

US · Generics Segment · Antiviral

Statement Geographical · Statement Business Segments · Product Or Service

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiviralMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-313866000 USD20240508Open filing evidence

US · Generics Segment · Central Nervous System

Statement Geographical · Statement Business Segments · Product Or Service

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-31109456000 USD20240508Open filing evidence

US · Generics Segment · Dermatology

Statement Geographical · Statement Business Segments · Product Or Service

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:DermatologyMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-3118975000 USD20240508Open filing evidence

US · Generics Segment · Other Therapeutic Classes

Statement Geographical · Statement Business Segments · Product Or Service

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-3118523000 USD20240508Open filing evidence

US · Generics Segment · Respiratory

Statement Geographical · Statement Business Segments · Product Or Service

Source dimensions srt:StatementGeographicalAxis=country:US;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:RespiratoryMember
PeriodValueUnitFiledEvidence
2024-01-01 – 2024-03-3111136000 USD20240508Open filing evidence

Non Us · Generics Segment

Statement Geographical · Statement Business Segments

Source dimensions srt:StatementGeographicalAxis=us-gaap:NonUsMember;us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-304508000 USD20241112Open filing evidence
2024-01-01 – 2024-09-307659000 USD20241112Open filing evidence
2024-04-01 – 2024-06-301430000 USD20240809Open filing evidence
2024-01-01 – 2024-06-303151000 USD20240809Open filing evidence
2024-01-01 – 2024-03-311721000 USD20240508Open filing evidence
2023-07-01 – 2023-09-30867000 USD20241112Open filing evidence
2023-01-01 – 2023-09-301714000 USD20241112Open filing evidence

Affordable Medicines Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30547109000 USD20261109Open filing evidence
2026-01-01 – 2026-09-301460259000 USD20261109Open filing evidence
2026-04-01 – 2026-06-30489913000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30913150000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31423237000 USD20260507Open filing evidence
2025-07-01 – 2025-09-30460741000 USD20261109Open filing evidence
2025-01-01 – 2025-09-301308874000 USD20261109Open filing evidence
2025-04-01 – 2025-06-30433425000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30848133000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31414708000 USD20260507Open filing evidence

Affordable Medicines Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30547109000 USD20261109Open filing evidence
2026-01-01 – 2026-09-301460259000 USD20261109Open filing evidence
2025-07-01 – 2025-09-30460741000 USD20261109Open filing evidence
2025-01-01 – 2025-09-301308874000 USD20261109Open filing evidence

Affordable Medicines Segment · Biosimilar

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:BiosimilarMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3077710000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30129139000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3017009000 USD20261109Open filing evidence
2025-01-01 – 2025-09-3070797000 USD20261109Open filing evidence

Affordable Medicines Segment · Ephinephrine Auto Injector

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:EphinephrineAutoInjectorMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3065163000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30169289000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3078940000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30193694000 USD20261109Open filing evidence

Affordable Medicines Segment · Injectable

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:InjectableMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3053805000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30160526000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3054368000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30123802000 USD20261109Open filing evidence

Affordable Medicines Segment · International

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:InternationalMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-304915000 USD20261109Open filing evidence
2026-01-01 – 2026-09-3017847000 USD20261109Open filing evidence
2025-07-01 – 2025-09-306288000 USD20261109Open filing evidence
2025-01-01 – 2025-09-309423000 USD20261109Open filing evidence

Affordable Medicines Segment · Oral Liquid

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:OralLiquidMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-309092000 USD20261109Open filing evidence
2026-01-01 – 2026-09-3031555000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3016415000 USD20261109Open filing evidence
2025-01-01 – 2025-09-3057842000 USD20261109Open filing evidence

Affordable Medicines Segment · Oral Solid

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:OralSolidMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30207517000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30553789000 USD20261109Open filing evidence
2025-07-01 – 2025-09-30180460000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30537675000 USD20261109Open filing evidence

Affordable Medicines Segment · Other Dosage Forms

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:OtherDosageFormsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3060841000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30189047000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3059662000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30184269000 USD20261109Open filing evidence

Affordable Medicines Segment · Subtotal Dosage Forms

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:SubtotalDosageFormsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30542194000 USD20261109Open filing evidence
2026-01-01 – 2026-09-301442412000 USD20261109Open filing evidence
2025-07-01 – 2025-09-30454453000 USD20261109Open filing evidence
2025-01-01 – 2025-09-301299451000 USD20261109Open filing evidence

Affordable Medicines Segment · Transdermal

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AffordableMedicinesSegmentMember;srt:ProductOrServiceAxis=amrx:TransdermalMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3068066000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30209067000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3047599000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30131372000 USD20261109Open filing evidence

Amneal Specialty Pharma Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AmnealSpecialtyPharmaSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30150262000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30432822000 USD20261109Open filing evidence
2025-07-01 – 2025-09-30125240000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30361580000 USD20261109Open filing evidence
2023-07-01 – 2023-09-3097304000 USD20231109Open filing evidence
2023-01-01 – 2023-09-30285976000 USD20231109Open filing evidence

Av KARE Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30165313000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30488319000 USD20261109Open filing evidence
2026-04-01 – 2026-06-30156989000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30323006000 USD20260806Open filing evidence
2026-01-01 – 2026-03-31166017000 USD20260507Open filing evidence
2025-01-01 – 2025-12-31744728000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30198532000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30533987000 USD20261109Open filing evidence
2025-04-01 – 2025-06-30163040000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30335455000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31172415000 USD20260507Open filing evidence
2024-01-01 – 2024-12-31662945000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30159485000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30492559000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30170411000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30333074000 USD20250807Open filing evidence
2024-01-01 – 2024-03-31162663000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31531749000 USD20260227Open filing evidence
2023-07-01 – 2023-09-30131879000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30382286000 USD20241112Open filing evidence

Av KARE Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30165313000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30488319000 USD20261109Open filing evidence
2025-07-01 – 2025-09-30198532000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30533987000 USD20261109Open filing evidence

Av KARE Segment · Government Label

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=amrx:GovernmentLabelMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3053385000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30163541000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3087755000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30183313000 USD20261109Open filing evidence

Av KARE Segment · Institutional

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=amrx:InstitutionalMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3010012000 USD20261109Open filing evidence
2026-01-01 – 2026-09-3031943000 USD20261109Open filing evidence
2025-07-01 – 2025-09-305853000 USD20261109Open filing evidence
2025-01-01 – 2025-09-3026994000 USD20261109Open filing evidence

Av KARE Segment · Distribution Service

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3092905000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30268984000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3096216000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30300774000 USD20261109Open filing evidence

Av KARE Segment · Distribution Service · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:DistributionServiceMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3081904000 USD20231109Open filing evidence
2023-01-01 – 2023-09-30248929000 USD20231109Open filing evidence

Av KARE Segment · Product And Service Other

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-309011000 USD20261109Open filing evidence
2026-01-01 – 2026-09-3023851000 USD20261109Open filing evidence
2025-07-01 – 2025-09-308708000 USD20261109Open filing evidence
2025-01-01 – 2025-09-3022906000 USD20261109Open filing evidence

Av KARE Segment · Product And Service Other · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:AvKARESegmentMember;srt:ProductOrServiceAxis=us-gaap:ProductAndServiceOtherMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-306660000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3017812000 USD20231109Open filing evidence

Generics Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember
PeriodValueUnitFiledEvidence
2024-07-01 – 2024-09-30427345000 USD20241112Open filing evidence
2024-01-01 – 2024-09-301245967000 USD20241112Open filing evidence
2024-04-01 – 2024-06-30427328000 USD20240809Open filing evidence
2024-01-01 – 2024-06-30818622000 USD20240809Open filing evidence
2024-01-01 – 2024-03-31391294000 USD20240508Open filing evidence
2023-01-01 – 2023-12-311471401000 USD20240314Open filing evidence
2023-07-01 – 2023-09-30390857000 USD20241112Open filing evidence
2023-01-01 – 2023-09-301108364000 USD20241112Open filing evidence

Generics Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-311471401000 USD20240314Open filing evidence
2023-07-01 – 2023-09-30390857000 USD20231109Open filing evidence
2023-01-01 – 2023-09-301108364000 USD20231109Open filing evidence

Generics Segment · Anti Infective · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3125885000 USD20240314Open filing evidence

Generics Segment · Antiviral · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:AntiviralMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3139910000 USD20240314Open filing evidence

Generics Segment · Cardiovascular System · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:CardiovascularSystemMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31139942000 USD20240314Open filing evidence

Generics Segment · Dermatology · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:DermatologyMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3170872000 USD20240314Open filing evidence
2023-07-01 – 2023-09-3017279000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3053232000 USD20231109Open filing evidence

Generics Segment · Gastroenterology · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:GastroenterologyMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3167519000 USD20240314Open filing evidence
2023-07-01 – 2023-09-3018858000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3053127000 USD20231109Open filing evidence

Generics Segment · Hormonal Allergy · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-30126425000 USD20231109Open filing evidence
2023-01-01 – 2023-09-30357711000 USD20231109Open filing evidence

Generics Segment · License Agreement · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-310 USD20240314Open filing evidence

Generics Segment · Metabolic Disease Endocrine · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-3011026000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3035227000 USD20231109Open filing evidence

Generics Segment · Other Therapeutic Classes · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31105106000 USD20240314Open filing evidence

Generics Segment · Respiratory · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:ProductOrServiceAxis=amrx:RespiratoryMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-307832000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3031783000 USD20231109Open filing evidence

Generics Segment · US · Anti Infective

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:AntiInfectiveMember
PeriodValueUnitFiledEvidence
2023-07-01 – 2023-09-307382000 USD20231109Open filing evidence
2023-01-01 – 2023-09-3018648000 USD20231109Open filing evidence

Generics Segment · US · Central Nervous System

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31369201000 USD20240314Open filing evidence
2023-07-01 – 2023-09-3096587000 USD20231109Open filing evidence
2023-01-01 – 2023-09-30264773000 USD20231109Open filing evidence

Generics Segment · US · Hormonal Allergy

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31451736000 USD20240314Open filing evidence

Generics Segment · US · Metabolic Disease Endocrine

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:MetabolicDiseaseEndocrineMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3145900000 USD20240314Open filing evidence

Generics Segment · US · Oncology

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:OncologyMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31110455000 USD20240314Open filing evidence

Generics Segment · US · Respiratory

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:RespiratoryMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-3142710000 USD20240314Open filing evidence

Generics Segment · Non Us

Statement Business Segments · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:GenericsSegmentMember;srt:StatementGeographicalAxis=us-gaap:NonUsMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-312165000 USD20240314Open filing evidence

Specialty Segment

Statement Business Segments

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30150262000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30432822000 USD20261109Open filing evidence
2026-04-01 – 2026-06-30149295000 USD20260806Open filing evidence
2026-01-01 – 2026-06-30282560000 USD20260806Open filing evidence
2025-01-01 – 2025-12-31528508000 USD20260227Open filing evidence
2025-07-01 – 2025-09-30125240000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30361580000 USD20261109Open filing evidence
2025-04-01 – 2025-06-30128043000 USD20260806Open filing evidence
2025-01-01 – 2025-06-30236340000 USD20260806Open filing evidence
2025-01-01 – 2025-03-31108297000 USD20250507Open filing evidence
2024-01-01 – 2024-12-31445749000 USD20260227Open filing evidence
2024-07-01 – 2024-09-30115638000 USD20251106Open filing evidence
2024-01-01 – 2024-09-30324913000 USD20251106Open filing evidence
2024-04-01 – 2024-06-30104041000 USD20250807Open filing evidence
2024-01-01 – 2024-06-30209275000 USD20250807Open filing evidence
2024-01-01 – 2024-03-31105234000 USD20250507Open filing evidence
2023-01-01 – 2023-12-31390457000 USD20260227Open filing evidence
2023-07-01 – 2023-09-3097304000 USD20241112Open filing evidence
2023-01-01 – 2023-09-30285976000 USD20241112Open filing evidence

Specialty Segment · Operating Segments

Statement Business Segments · Consolidation Items

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ConsolidationItemsAxis=us-gaap:OperatingSegmentsMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31390457000 USD20240314Open filing evidence

Specialty Segment · Central Nervous System

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3096177000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30274904000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3077631000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30228666000 USD20261109Open filing evidence

Specialty Segment · Hormonal Allergy

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-3043148000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30121179000 USD20261109Open filing evidence
2025-07-01 – 2025-09-3037685000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30107302000 USD20261109Open filing evidence

Specialty Segment · Hormonal Allergy · US

Statement Business Segments · Product Or Service · Statement Geographical

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember;srt:StatementGeographicalAxis=country:US
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-09-3082268000 USD20231109Open filing evidence

Specialty Segment · License Agreement

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:LicenseAgreementMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-301488000 USD20261109Open filing evidence
2026-01-01 – 2026-09-301488000 USD20261109Open filing evidence
2025-07-01 – 2025-09-300 USD20261109Open filing evidence
2025-01-01 – 2025-09-30500000 USD20261109Open filing evidence

Specialty Segment · Other Therapeutic Classes

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:OtherTherapeuticClassesMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-309449000 USD20261109Open filing evidence
2026-01-01 – 2026-09-3035251000 USD20261109Open filing evidence
2025-07-01 – 2025-09-309924000 USD20261109Open filing evidence
2025-01-01 – 2025-09-3025112000 USD20261109Open filing evidence

Specialty Segment · Subtotal Therapeutic Classes

Statement Business Segments · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:ProductOrServiceAxis=amrx:SubtotalTherapeuticClassesMember
PeriodValueUnitFiledEvidence
2026-07-01 – 2026-09-30148774000 USD20261109Open filing evidence
2026-01-01 – 2026-09-30431334000 USD20261109Open filing evidence
2025-07-01 – 2025-09-30125240000 USD20261109Open filing evidence
2025-01-01 – 2025-09-30361080000 USD20261109Open filing evidence

Specialty Segment · US · Central Nervous System

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:CentralNervousSystemMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31249981000 USD20240314Open filing evidence

Specialty Segment · US · Hormonal Allergy

Statement Business Segments · Statement Geographical · Product Or Service

Source dimensions us-gaap:StatementBusinessSegmentsAxis=amrx:SpecialtySegmentMember;srt:StatementGeographicalAxis=country:US;srt:ProductOrServiceAxis=amrx:HormonalAllergyMember
PeriodValueUnitFiledEvidence
2023-01-01 – 2023-12-31110486000 USD20240314Open filing evidence